We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-0.6%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.74B
AUM Growth
+$257M
Cap. Flow
-$141M
Cap. Flow %
-5.14%
Top 10 Hldgs %
33.17%
Holding
165
New
42
Increased
42
Reduced
15
Closed
34

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$60.9M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$57M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$40M
4
WBA
Walgreens Boots Alliance
WBA
+$31.6M
5
GMED icon
Globus Medical
GMED
+$26.3M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$102M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$40.6M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$23.8M
4
AMAG
AMAG Pharmaceuticals
AMAG
+$20.7M
5
HCA icon
HCA Healthcare
HCA
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 46.9%
2 Financials 2.94%
3 Technology 0.55%
4 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYBX
76
DELISTED
CYBERONICS INC
CYBX
$5.63M 0.21%
110,000
+55,110
+100% +$3.18M
BEAT
77
DELISTED
BioTelemetry, Inc.
BEAT
$5.56M 0.2%
+828,400
New +$5.81M
LMNS
78
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$5.33M 0.19%
597,866
+298,900
+100% +$2.74M
HCA icon
79
HCA Healthcare
HCA
$82.3B
$5.03M 0.18%
71,303
-308,886
-81% -$20.4M
GNCA
80
DELISTED
Genocea Biosciences, Inc.
GNCA
$5.02M 0.18%
69,282
+8,880
+15% +$972K
THC icon
81
Tenet Healthcare
THC
$16.8B
$4.93M 0.18%
82,960
-283,996
-77% -$15.8M
OSIR
82
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$4.88M 0.18%
388,039
+344,594
+793% +$4.91M
KBIO
83
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$4.77M 0.17%
384,372
+36,024
+10% +$497K
RIGL icon
84
Rigel Pharmaceuticals
RIGL
$750M
$4.65M 0.17%
239,786
– –
DSCI
85
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$4.62M 0.17%
554,057
+36,157
+7% +$335K
CASC
86
DELISTED
Cascadian Therapeutics, Inc.
CASC
$4.33M 0.16%
+375,439
New +$5.74M
MRGE
87
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$4.26M 0.16%
1,937,696
+279,000
+17% +$678K
SCYX icon
88
SCYNEXIS
SCYX
$42.4M
$4.16M 0.15%
7,041
-69
-1% -$39.9K
CDNA icon
89
CareDx
CDNA
$2.05B
$4.03M 0.15%
+575,000
New +$5.53M
ADPT
90
DELISTED
Adeptus Health Inc
ADPT
$4.01M 0.15%
+161,123
New +$4.21M
KIN
91
DELISTED
Kindred Biosciences, Inc.
KIN
$3.79M 0.14%
409,863
+34,863
+9% +$471K
EGRX
92
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3.6M 0.13%
284,653
– –
LPDX
93
DELISTED
LIPOSCIENCE INC COM
LPDX
$3.52M 0.13%
679,180
-703,170
-51% -$2.3M
CBAY
94
DELISTED
Cymabay Therapeutics
CBAY
$3.51M 0.13%
+513,206
New +$3.15M
ANTH
95
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.25M 0.12%
211,482
– –
TVRD
96
Tvardi Therapeutics
TVRD
$30M
$3.21M 0.12%
+10,639
New +$4.37M
FOLD
97
DELISTED
Amicus Therapeutics
FOLD
$2.86M 0.1%
+480,000
New +$2.51M
FOMX
98
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.43M 0.09%
+446,452
New +$2.56M
ALKS icon
99
Alkermes
ALKS
$8.79B
$2.36M 0.09%
55,000
+51,000
+1,275% +$2.29M
BIND
100
DELISTED
BIND THERAPEUTICS INC
BIND
$2.35M 0.09%
+274,000
New +$2.7M
2 3
4
5 6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2014 Portfolio in Review

As of Q3 2014, Deerfield Management held 165 positions worth $2.74B, up 10% from $2.49B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Deerfield Management withdrew a net $141M in Q3 2014, closing 34 positions and reducing 15 holdings. Its most notable exit was INTERMUNE INC, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 42% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Adverum Biotechnologies worth $70M.

  • Deerfield Management's largest Q3 2014 buy was Adverum Biotechnologies: 204,768 shares worth $70M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014, an estimated $57M increase.
  • Deerfield Management's biggest Q3 2014 reduction was Keryx Biopharmaceuticals Inc, cutting an estimated $40.6M.
  • Deerfield Management fully exited INTERMUNE INC in Q3 2014, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 33% of its $2.74B portfolio in Q3 2014.
  • Deerfield Management opened 42 new positions and closed 34 in Q3 2014.
  • Deerfield Management's portfolio value rose 10% quarter-over-quarter to $2.74B.

Based on Deerfield Management's 13F filing for Q3 2014, filed 14 Nov 2014.